Y. Zhan

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Parantu K. Shah, A. Protopopov, B. Vangamudi, 2015, Cancer research.

Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2.

G. Poncet-Montange, Gilbert R. Lee, J. Ladbury, 2015, The Biochemical journal.

Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery

B. Vangamudi, M. Kost-Alimova, M. Barton, 2015, Epigenetics & Chromatin.

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.

G. Poncet-Montange, G. Subramanian, M. Kost-Alimova, 2016, Journal of medicinal chemistry.

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Parantu K. Shah, A. Protopopov, B. Vangamudi, 2015, Cancer research.